CTKB — Cytek Biosciences Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapNeutral

Annual income statement for Cytek Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	92.8	128	164	193	200
Cost of Revenue
Gross Profit	51.7	79.1	101	109	111
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Total Operating Expenses	79.2	119	166	221	221
Operating Profit	13.7	9.16	-1.8	-27.8	-20.5
Total Net Non Operating Interest Income / Expense
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	14.4	5.94	1.26	-15.7	-5.7
Provision for Income Taxes
Net Income After Taxes	19.4	3.03	2.48	-12.1	-6.02
Minority Interest
Net Income Before Extraordinary Items
Net Income	19.4	3	2.58	-12.1	-6.02
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	3.22	0	2.58	-12.1	-6.02
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.025	0.001	0.019	-0.09	-0.046
Dividends per Share